Literature DB >> 1864284

Newly documented antimicrobial activity of quinolones.

Y X Furet1, J C Pechère.   

Abstract

The improved antimicrobial activity of newer fluoroquinolones and novel applications recently found for the drugs already marketed are reviewed. Several new compounds are more active against gram-positive bacteria than the presently marketed fluoroquinolones. WIN 57273, the most potent compound in vitro on a weight basis, is 16 to 128 times more active than ciprofloxacin against various staphylococci, streptococci, Enterococcus spp., Corynebacterium spp., Listeria monocytogenes and Bacillus spp. BMY 40062, PD 117558, PD 127391, sparfloxacin, temafloxacin and tosufloxacin also show enhanced in vitro efficacy against these species. These drugs also possess increased activity against various anaerobes, notably Clostridium perfringens, Clostridium difficile and the Bacteroides fragilis group. Mycobacterium tuberculosis, rapidly growing mycobacteria other than Mycobacterium chelonae, and Mycobacterium leprae are often susceptible to quinolones displaying bactericidal activity which is potentially useful for curing difficult-to-treat mycobacteriosis. In addition, a number of new products, notably those containing a cyclopropyl group, are more active than reference fluoroquinolones against Mycobacterium leprae. Sparfloxacin, BMY 40062 and WIN 57273 compare favorably with older fluoroquinolones in the killing of intracellular Legionella spp., and several of the newer compounds have greater antichlamydial potency. Improved antibacterial activity has also been found against Mycoplasma hominis, Ureaplasma urealyticum, Acinetobacter spp. and Pseudomonas maltophilia. By contrast, the newer quinolones have similar or less activity against Pseudomonas aeruginosa and Enterobacteriaceae. Recently, pefloxacin, ofloxacin and ciprofloxacin were found to be active against protozoa, including Plasmodium spp., Trypanosoma cruzi and Leishmania donovani, but not against Toxoplasma gondii. In the near future, more specific research testing unusual pathogens may lead to the identification of quinolones with more selective activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864284     DOI: 10.1007/bf01966997

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  44 in total

Review 1.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin.

Authors:  T Butler; M Cartagenova; D Dunn
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

3.  [Therapeutic effect of ofloxacin (DL 8280) on pulmonary tuberculosis. (Report of a one year-administration study on sixteen treatment-failure patients)].

Authors:  M Tsukamura; E Nakamura; S Yoshii; M Yanase; Y Yasuda; H Amano
Journal:  Kekkaku       Date:  1985-06

4.  Ciprofloxacin and malaria.

Authors:  S Krishna; T M Davis; P C Chan; R A Wells; K J Robson
Journal:  Lancet       Date:  1988-05-28       Impact factor: 79.321

5.  Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.

Authors:  D M Yajko; P S Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

6.  Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae.

Authors:  S G Franzblau; K E White
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Efficacy of ciprofloxacin against Leptospira interrogans serogroup icterohaemorrhagiae.

Authors:  I Shalit; A Barnea; A Shahar
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

8.  In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.

Authors:  J Fung-Tomc; J V Desiderio; Y H Tsai; G Warr; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

10.  In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.

Authors:  J Texier-Maugein; M Mormède; J Fourche; C Bébéar
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

View more
  9 in total

Review 1.  The value of new antimicrobial agents.

Authors:  J H Wagenvoort
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

Review 2.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  In vitro antimicrobial susceptibilities of Nocardia species.

Authors:  N Khardori; R Shawar; R Gupta; B Rosenbaum; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 4.  'FAS't inhibition of malaria.

Authors:  Avadhesha Surolia; T N C Ramya; V Ramya; Namita Surolia
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

5.  The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis.

Authors:  Paolo Bianciardi; Antonio Fasanella; Valentina Foglia Manzillo; Teresa Trotta; Annalisa Pagano; Simona Sorino; Luigi Gradoni; Gaetano Oliva
Journal:  Parasitol Res       Date:  2004-07-23       Impact factor: 2.289

6.  Relative beta-lactamase- and transpeptidase-inhibitory activities of the new quinolone WIN-57273 in Staphylococcus aureus.

Authors:  Y X Furet; C Lucain; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

7.  In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.

Authors:  N Khardori; H Nguyen; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

8.  Validation of Putative Apicoplast-Targeting Drugs Using a Chemical Supplementation Assay in Cultured Human Malaria Parasites.

Authors:  Geoffrey Ian McFadden; Christopher Dean Goodman; Taher Uddin
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 9.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.